-
1
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
-
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
-
(2002)
Nat Med
, vol.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
Tamura, H.4
Hirano, F.5
Flies, D.B.6
-
2
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
3
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
-
(2015)
N Engl J Med
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
-
4
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
-
5
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32.
-
(2015)
N Engl J Med
, vol.372
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
Arance, A.4
Grob, J.J.5
Mortier, L.6
-
6
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
-
7
-
-
84946488591
-
Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck
-
Thierauf J, Veit JA, Affolter A, Bergmann C, Grunow J, Laban S, et al. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Res 2015; 25:503-9.
-
(2015)
Melanoma Res
, vol.25
, pp. 503-509
-
-
Thierauf, J.1
Veit, J.A.2
Affolter, A.3
Bergmann, C.4
Grunow, J.5
Laban, S.6
-
8
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
-
(2012)
Sci Transl Med
, vol.4
, pp. 127-137
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
-
9
-
-
84941966146
-
Characterization of PD-L1 expression and associated t-cell infiltrates in metastatic melanoma samples from variable anatomic sites
-
Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. Characterization of PD-L1 expression and associated t-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 2015;21:3052-60.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3052-3060
-
-
Kluger, H.M.1
Zito, C.R.2
Barr, M.L.3
Baine, M.K.4
Chiang, V.L.5
Sznol, M.6
-
10
-
-
84941637917
-
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600
-
Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, et al. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 2015;26:1980-7.
-
(2015)
Ann Oncol
, vol.26
, pp. 1980-1987
-
-
Massi, D.1
Brusa, D.2
Merelli, B.3
Falcone, C.4
Xue, G.5
Carobbio, A.6
-
11
-
-
84927613720
-
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
-
Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol 2014;25:2433-42.
-
(2014)
Ann Oncol
, vol.25
, pp. 2433-2442
-
-
Massi, D.1
Brusa, D.2
Merelli, B.3
Ciano, M.4
Audrito, V.5
Serra, S.6
-
12
-
-
77950283280
-
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
-
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757-66.
-
(2010)
Cancer
, vol.116
, pp. 1757-1766
-
-
Hino, R.1
Kabashima, K.2
Kato, Y.3
Yagi, H.4
Nakamura, M.5
Honjo, T.6
-
13
-
-
84926678589
-
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials
-
Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28:245-53.
-
(2015)
Pigment Cell Melanoma Res
, vol.28
, pp. 245-253
-
-
Madore, J.1
Vilain, R.E.2
Menzies, A.M.3
Kakavand, H.4
Wilmott, J.S.5
Hyman, J.6
-
14
-
-
84935009372
-
Genomic classification of cutaneous melanoma
-
The Cancer Genome Atlas Network
-
The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161:1681-96.
-
(2015)
Cell
, vol.161
, pp. 1681-1696
-
-
-
15
-
-
75249087100
-
EdgeR: A Bioconductor package for differential expression analysis of digital gene expression data
-
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40.
-
(2010)
Bioinformatics
, vol.26
, pp. 139-140
-
-
Robinson, M.D.1
McCarthy, D.J.2
Smyth, G.K.3
-
16
-
-
84903146127
-
Robustly detecting differential expression in RNA sequencing data using observation weights
-
Zhou X, Lindsay H, Robinson MD. Robustly detecting differential expression in RNA sequencing data using observation weights. Nucleic Acids Res 2014;42:e91.
-
(2014)
Nucleic Acids Res
, vol.42
, pp. e91
-
-
Zhou, X.1
Lindsay, H.2
Robinson, M.D.3
-
17
-
-
27344435774
-
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
-
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 15545-15550
-
-
Subramanian, A.1
Tamayo, P.2
Mootha, V.K.3
Mukherjee, S.4
Ebert, B.L.5
Gillette, M.A.6
-
19
-
-
84871342666
-
Cutoff Finder: A comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization
-
Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012;7:e51862.
-
(2012)
PLoS One
, vol.7
, pp. e51862
-
-
Budczies, J.1
Klauschen, F.2
Sinn, B.V.3
Gyorffy, B.4
Schmitt, W.D.5
Darb-Esfahani, S.6
-
21
-
-
84865957345
-
Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma
-
Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, et al. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer 2012;118:4519-29.
-
(2012)
Cancer
, vol.118
, pp. 4519-4529
-
-
Murali, R.1
Brown, P.T.2
Kefford, R.F.3
Scolyer, R.A.4
Thompson, J.F.5
Atkins, M.B.6
-
22
-
-
84894460266
-
Intrapatient homogeneity of BRAFV600E expression in melanoma
-
Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol 2014;38:377-82.
-
(2014)
Am J Surg Pathol
, vol.38
, pp. 377-382
-
-
Menzies, A.M.1
Lum, T.2
Wilmott, J.S.3
Hyman, J.4
Kefford, R.F.5
Thompson, J.F.6
-
23
-
-
84901459546
-
ImmPort: Disseminating data to the public for the future of immunology
-
Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014;58:234-9.
-
(2014)
Immunol Res
, vol.58
, pp. 234-239
-
-
Bhattacharya, S.1
Andorf, S.2
Gomes, L.3
Dunn, P.4
Schaefer, H.5
Pontius, J.6
-
24
-
-
0035070697
-
Regulation of proteasome complexes by gamma-interferon and phosphorylation
-
Rivett AJ, Bose S, Brooks P, Broadfoot KI. Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie 2001; 83:363-6.
-
(2001)
Biochimie
, vol.83
, pp. 363-366
-
-
Rivett, A.J.1
Bose, S.2
Brooks, P.3
Broadfoot, K.I.4
-
25
-
-
84872595484
-
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma
-
Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013;133:509-17.
-
(2013)
J Invest Dermatol
, vol.133
, pp. 509-517
-
-
Mann, G.J.1
Pupo, G.M.2
Campain, A.E.3
Carter, C.D.4
Schramm, S.J.5
Pianova, S.6
-
26
-
-
84904024273
-
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
-
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-74.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5064-5074
-
-
Taube, J.M.1
Klein, A.2
Brahmer, J.R.3
Xu, H.4
Pan, X.5
Kim, J.H.6
-
27
-
-
4344671644
-
Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance
-
Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-73.
-
(2004)
Cancer Res
, vol.64
, pp. 2865-2873
-
-
Zippelius, A.1
Batard, P.2
Rubio-Godoy, V.3
Bioley, G.4
Lienard, D.5
Lejeune, F.6
-
28
-
-
84863928141
-
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity
-
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res 2012;18:3834-45.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3834-3845
-
-
Loo, D.1
Alderson, R.F.2
Chen, F.Z.3
Huang, L.4
Zhang, W.5
Gorlatov, S.6
-
29
-
-
12444262173
-
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy
-
Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 2005;174:1462-71.
-
(2005)
J Immunol
, vol.174
, pp. 1462-1471
-
-
Chang, C.C.1
Campoli, M.2
Restifo, N.P.3
Wang, X.4
Ferrone, S.5
-
30
-
-
84920774335
-
Exploiting natural killer cells for therapy of melanoma
-
H€olsken O, Miller M, Cerwenka A. Exploiting natural killer cells for therapy of melanoma. J Dtsch Dermatol Ges 2015;13:23-9.
-
(2015)
J Dtsch Dermatol Ges
, vol.13
, pp. 23-29
-
-
Holsken, O.1
Miller, M.2
Cerwenka, A.3
-
31
-
-
84956958113
-
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
-
Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, et al. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 2016;46:409-19.
-
(2016)
Eur J Immunol
, vol.46
, pp. 409-419
-
-
Sottile, R.1
Pangigadde, P.N.2
Tan, T.3
Anichini, A.4
Sabbatino, F.5
Trecroci, F.6
-
32
-
-
84882837534
-
Signatures of mutational processes in human cancer
-
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-21.
-
(2013)
Nature
, vol.500
, pp. 415-421
-
-
Alexandrov, L.B.1
Nik-Zainal, S.2
Wedge, D.C.3
Aparicio, S.A.4
Behjati, S.5
Biankin, A.V.6
-
33
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
-
(2014)
N Engl J Med
, vol.371
, pp. 2189-2199
-
-
Snyder, A.1
Makarov, V.2
Merghoub, T.3
Yuan, J.4
Zaretsky, J.M.5
Desrichard, A.6
-
34
-
-
84880276438
-
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
-
Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19:747-52.
-
(2013)
Nat Med
, vol.19
, pp. 747-752
-
-
Robbins, P.F.1
Lu, Y.C.2
El-Gamil, M.3
Li, Y.F.4
Gross, C.5
Gartner, J.6
-
35
-
-
84872841412
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
-
van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42.
-
(2013)
J Clin Oncol
, vol.31
, pp. e439-e442
-
-
Van Rooij, N.1
Van Buuren, M.M.2
Philips, D.3
Velds, A.4
Toebes, M.5
Heemskerk, B.6
-
36
-
-
84961323160
-
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4? T cells in human melanoma
-
Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4? T cells in human melanoma. Nat Med 2015; 21:81-5.
-
(2015)
Nat Med
, vol.21
, pp. 81-85
-
-
Linnemann, C.1
Van Buuren, M.M.2
Bies, L.3
Verdegaal, E.M.4
Schotte, R.5
Calis, J.J.6
-
37
-
-
84903846565
-
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions
-
Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 2014;20:3401-10.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 3401-3410
-
-
Lu, Y.C.1
Yao, X.2
Crystal, J.S.3
Li, Y.F.4
El-Gamil, M.5
Gross, C.6
-
38
-
-
84920962202
-
Molecular and genetic properties of tumors associated with local immune cytolytic activity
-
Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48-61.
-
(2015)
Cell
, vol.160
, pp. 48-61
-
-
Rooney, M.S.1
Shukla, S.A.2
Wu, C.J.3
Getz, G.4
Hacohen, N.5
-
39
-
-
84899836282
-
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
-
Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014;24:743-50.
-
(2014)
Genome Res
, vol.24
, pp. 743-750
-
-
Brown, S.D.1
Warren, R.L.2
Gibb, E.A.3
Martin, S.D.4
Spinelli, J.J.5
Nelson, B.H.6
-
40
-
-
84928761118
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
-
41
-
-
84943516465
-
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
-
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015;350:207-11.
-
(2015)
Science
, vol.350
, pp. 207-211
-
-
Van Allen, E.M.1
Miao, D.2
Schilling, B.3
Shukla, S.A.4
Blank, C.5
Zimmer, L.6
|